Companies › Beijing Mabworks Biotech
5 active drug programs in 8 registered trials: 5 Phase 1, 2 Phase 3, 1 Phase 2; Oncology, Genitourinary, Neurology, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Recombinant Humanized Monoclonal Antibody MIL62 Injection Monoclonal antibody | – | Phase 3 | Neuromyelitis Optica Spectrum Disorder; Systemic Lupus Erythematosus; Lupus Nephritis | Mar 2027 |
| MBS303 T-cell bispecific antibody targeting CD19 on B cells | CD19 | Phase 1 | Non-Hodgkin's Lymphoma | Nov 2026 |
| Recombinant Humanized Monoclonal Antibody MIL97 | – | Phase 1 | Advanced or Metastatic Solid Tumor | Dec 2026 |
| MBS314 asymmetric trivalent tri-specific humanized antibody | – | Phase 1 | Relapsed or Refractory Multiple Myeloma | Mar 2028 |
| MIL116 anti-APRIL monoclonal antibody | APRIL | Phase 1 | Immunoglobulin A Nephropathy | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05796206 | Recombinant Humanized Monoclonal Antibody MIL62 Injection | Phase 2 | Systemic Lupus Erythematosus | Immunology | Nov 2024 |
| NCT07044115 | Recombinant Humanized Monoclonal Antibody MIL62 Injection | Phase 1 | Lupus Nephritis | Immunology | Jan 2025 |
| NCT05806099 | MBS303 | Phase 1 | Non-Hodgkin's Lymphoma | Oncology | Nov 2026 |
| NCT04965077 | Recombinant Humanized Monoclonal Antibody MIL97 | Phase 1 | Advanced or Metastatic Solid Tumor | Oncology | Dec 2026 |
| NCT05314010 | Recombinant Humanized Monoclonal Antibody MIL62 Injection | Phase 3 | Neuromyelitis Optica Spectrum Disorder | Neurology | Mar 2027 |
| NCT06232096 | MBS314 | Phase 1 | Relapsed or Refractory Multiple Myeloma | Oncology | Mar 2028 |
| NCT07375758 | MIL116 | Phase 1 | Immunoglobulin A Nephropathy | Genitourinary | Jun 2028 |
| NCT07405970 | Recombinant Humanized Monoclonal Antibody MIL62 Injection | Phase 3 | Systemic Lupus Erythematosus | Immunology | Dec 2028 |
Bio-Thera Solutions Jemincare Tanabe Pharma BioRay Pharmaceutical Nanjing Sanhome Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.